Scholarlink

Background <p>Chemoresistance remains a major challenge in colorectal cancer (CRC) treatment. Metabolic reprogramming is a cancer hallmark, with the pentose phosphate pathway (PPP) playing a ceral role. This study aimed to investigate the role of the long noncoding RNA MAFG-AS1 in CRC chemoresistance and its underlying mechanism.</p> Methods <p>MAFG-AS1 expression was analyzed using TCGA data. Functional roles were assessed via RNA interference, overexpression, RNA pull-down, RIP, metabolic flux analysis, isotope tracing, and xenograft models, combined with qPCR, Western blot, flow cytometry, and IHC. Statistical analyses used t-tests and ANOVA.</p> Results <p>MAFG-AS1 was upregulated in CRC, driven transcriptionally by c-Myc. It directly bound to and stabilized G6PD homodimers, enhancing its enzymatic activity. This activated the PPP, increased NADPH production, reduced ROS levels, maintained redox homeostasis, and promoted CRC cell proliferation and tumor growth. MAFG-AS1 knockdown sensitized CRC cells to cisplatin and oxaliplatin.</p> Conclusion <p>MAFG-AS1 promotes metabolic reprogramming and reduces platinum sensitivity in CRC by enhancing G6PD-dependent PPP flux and redox buffering capacity. Targeting the MAFG-AS1–G6PD axis may represent a potential strategy to improve the efficacy of platinum-based chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The MAFG-AS1/G6PD axis reduces platinum sensitivity in colorectal cancer through pentose phosphate pathway activation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Jia Hui Kou,
  • Yujie Yao,
  • Wen Jin Li,
  • Jiajie Zou,
  • Luke Kong,
  • Junqi Zheng,
  • Yi Meng Yue,
  • Man Man Han,
  • Su Tang Guo

摘要

Background

Chemoresistance remains a major challenge in colorectal cancer (CRC) treatment. Metabolic reprogramming is a cancer hallmark, with the pentose phosphate pathway (PPP) playing a ceral role. This study aimed to investigate the role of the long noncoding RNA MAFG-AS1 in CRC chemoresistance and its underlying mechanism.

Methods

MAFG-AS1 expression was analyzed using TCGA data. Functional roles were assessed via RNA interference, overexpression, RNA pull-down, RIP, metabolic flux analysis, isotope tracing, and xenograft models, combined with qPCR, Western blot, flow cytometry, and IHC. Statistical analyses used t-tests and ANOVA.

Results

MAFG-AS1 was upregulated in CRC, driven transcriptionally by c-Myc. It directly bound to and stabilized G6PD homodimers, enhancing its enzymatic activity. This activated the PPP, increased NADPH production, reduced ROS levels, maintained redox homeostasis, and promoted CRC cell proliferation and tumor growth. MAFG-AS1 knockdown sensitized CRC cells to cisplatin and oxaliplatin.

Conclusion

MAFG-AS1 promotes metabolic reprogramming and reduces platinum sensitivity in CRC by enhancing G6PD-dependent PPP flux and redox buffering capacity. Targeting the MAFG-AS1–G6PD axis may represent a potential strategy to improve the efficacy of platinum-based chemotherapy.